MEKanistic has developed a first-in-class highly targeted compound which blocks two key pathways (EGFR and PI3K) responsible for signaling in cancer cell growth. In preclinical animal studies, this novel dual inhibitor has demonstrated impressive tumor shrinkage and tolerability.

How do we regulate kinase activity to arrest cancer activity but not enough to affect healthy cells? With over 500 unique kinases in the human kinome, targeting the right kinase(s) for cancer treatment is akin to finding the right kinase in the kinome haystack. Herein lies the paradox of selectively regulating kinase activity for anti-cancer activity while avoiding unmanageable toxicity of normal tissues.

Dr. LoRusso is a highly experienced oncologist and translational scientist with over 30 years of experience in drug development and clinical research. She is currently a Professor of Medicine and Associate Director for Innovative Medicine at Yale Cancer Center, and President-Elect of American Association for Cancer Research.

Led by cancer research pioneers, MEKanistic introduces a breakthrough drug that more effectively shrinks tumors–with less toxicity in preclinical trials.